Connect with us

Insight

What the NHS 10-Year Health Plan means for women and where it “falls short”

Published

on

The government’s 10-year plan for the NHS promises bold transformation, with a move towards digital innovation, and more focus on prevention over treatment, but does it go far enough to address the UK’s gender health gap?

Health Secretary Wes Streeting has revealed his vision for the UK’s public healthcare system, promising to transform the NHS over the next decade, in the government’s Fit for the Future report.

From a renewed focus on maternity care, to ambitions to eliminate cervical cancer by 2040, the government says its 10-year plan will play a fundamental role in delivering its commitment to  women’s health “never again being ignored”.

 

Currently, the UK has the largest gender health gap in the G20, with the average woman spending nearly a quarter of her life in poor health compared to a fifth for men.

Yet while the plan has been described as a “strong foundation”, crucial details about how its promises will be delivered are yet to be published, and some say the lack of specific action to address the gender health gap mean it may “fall short” for women.

Community, prevention and digitisation— what the government has promised

The NHS 10 year plan is underpinned by three key pillars; a move from hospital to community, sickness to prevention and from analogue to digital.

A focus on prevention, rather than sickness, promises to deliver better access to screening, and allow better use of health data to enable more predictive and pre-emptive care.

Plans to increase uptake of HPV vaccinations aim to help the NHS reach its ambitious target of eliminating cervical cancer by 2040. Meanwhile, universal newborn genomic testing and an introduction to polygenic risk scoring will be used to identify potential risks to child and maternal health early and help predict susceptibility to diseases.

The government has also committed to a national independent investigation into maternity and neonatal services, setting out plans for the establishment of a national maternity and neonatal taskforce, chaired by the Secretary of State, as well as a national action plan co-produced with bereaved families.

Placing more focus on neighbourhood health centres, rather than hospital treatment, will enable more people to access health services closer to home, according to the proposals, while an increased focus on the digitalisation of the NHS aims to make services faster, more convenient, and more personalised.

All patients will gain access to a single, digital health record, and the NHS app will be expanded allowing patients to book appointments, manage long-term conditions, reproductive health and medications, and coordinate care for children or elderly family members.

My Children, a digital alternative to what has been known for decades in maternity care as the ‘red book’ also aims to make it easier to manage children’s healthcare and medical records.

Speaking following the publication of the plan on Thursday 3 July, Streeting described this as a “meaningful advancement”, giving parents “practical tools when they need them most”.

“This isn’t just about convenience… It’s about recognising the realities of modern parenthood and removing unnecessary barriers to good healthcare,” he said.

“From offering timely, advice about feeding and weaning in those first months to providing guidance about adolescent mental health years later, this digital companion adapts to your family’s changing needs.”

Where the plan “falls short” on women’s health

The plan’s proposals for maternity care have been welcomed by the Royal College of Obstetricians and Gynaecologists (RCOG), with many women not receiving the “personalised, high-quality care they deserve”.

However, president, Professor Ranee Thakar, has suggested it lacks clarity on how it will address many of the the issues contributing to the gender health gap.

“While the plan lays strong foundations, it falls short in pledging to eliminate the gender health gap that is costing women years of life and good health,” Prof Thakar said in statement on Thursday.

“Today’s plan must mark a move away from treating women’s health as a collection of niche issues towards offering women excellent, joined-up care across their life course, with investment in the women’s health workforce, Femtech and research.”

Despite the fact that one in three women in the UK will suffer from a reproductive or gynaecological problem, less than 2.5 per cent of publicly funded research is dedicated solely to reproductive health.

Thakar added: “A huge opportunity may be missed without a clear focus on delivering better for women. We would like to see the Women’s Health Strategy for England reset quickly, to work alongside the 10-Year Plan in driving improvements in women’s health access, experiences and outcomes, particularly for minority ethnic women and those in the most socially deprived areas.”

The Women’s Health Strategy, developed and published in 2022, promised to address the inequalities in the health and care system, by providing better care for menstrual and gynaecological conditions, expanding women’s health hubs, improving maternity care and accelerating research into women’s health.

Some have been critical of the roll out of the strategy, accusing the former Conservative government of using it as a “short-term vote winner” and failing to fund it properly. A total of £25m was allocated to fund one-stop-shop women’s health hubs across the country for two years, compared to £240m which was spent on the Rwanda deportation scheme.

The role of women’s health hubs

The RCOG has called for the acceleration of women’s health hubs, which its believes could play a “crucial role” in establishing the neighbourhood care model which Streeting has promised in his 10-year plan.

Hubs bring healthcare services together, making the referral process easier and allowing women to see see different specialists, therapists and diagnostic teams under one roof, which can be beneficial for those managing complex symptoms or chronic health issues.

However according to Dr Nikki Kanani, a GP specialising in women’s health and a former director of primary care for NHS England, many are still in the pilot stage and services are stretched due to a lack of healthcare professionals trained in women’s health.

“What we need to do is follow through on the commitment of the strategy, to understand what good looks like and invest in scaling that,” she tells Femtech World.

“We need to treat hubs as a core part of the system, not just a side project,” she tells Femtech World.

“We need to understand what good looks like and invest in scaling that. That needs to be clearly set out with nationally-protected funding and ICB accountability. We need to upscale across primary care, we need roles that reflect the breadth of the knowledge that’s needed, and we need protected time for clinicians to work in these spaces.”

Dr Kanani also believes hubs also need to move beyond focusing on reproductive issues to other areas of healthcare where women are traditonally “dismissed” and “deprioritised”, such as cardiovascular care and mental health services.

Alongside this, incentivised targets for gender and ethnicity gaps in diagnosis, referrals and outcomes, as well as system-wide women’s health leads, could be practical next steps to ensure women’s health is prioritised across the NHS, Dr Kanani says.

Increased investment in private innovators

The government has promised to embrace technologies such as AI, genomics, wearables and robotics, to improve clinical outcomes and reduce clinician workload, which could see a shift towards more public-private partnerships in the NHS and more investment in private innovators.

Dr Kanani says this would be “welcome”, but innovators seeking NHS partnerships, especially in the women’s health space, will need to consider factors such as regulator requirements, responsible data-gathering and the practicalities of training clinicians.

“Any femtech company innovating a point of care solution should be thinking not just of their tool, but also how their tool improves decision-making, documentation and communication, she says.

“We can roll out thousands of tools, but frontline clinicians are understandably time-poor. Part of your job as a responsible innovator, is to say ‘here is my solution, let’s train you and make sure it’s easy to use and deploy’.”

Equity needs more than strategy

The promises of the 10-year plan are bold and ambitious, but how effective it will be— especially for women— remains to be seen.

A planned chapter explaining how the proposed changes would be delivered was not published alongside the rest of the plan on Thursday, and is now expected later this year.

Dr Kanani says how the plan is delivered will be crucial in determining how far it goes to improve women’s healthcare.

“There are some important steps in the 10-year plan, but health equity for women, particularly those from minoritised, marginalised and underserved communities, won’t be achieved through strategy alone. We need a really deep, system-wide culture shift,” she says.

“Equity needs more than just the narrative of equal access, it needs tailored design. Care models, research, workforce, all need to be actively built around these women and communities.”

Dr Kanani adds: “It could be transformational for women, but only if it’s designed intentionally around the realities of women’s lives.”

News

UK report warns against ‘financial half measures’ for women’s health

Published

on

The Women and Equalities Committee (WEC) has warned against “financial half measures” on women’s health as the government published its response to the report.

Ministers launched the renewed Women’s Health Strategy in April after the committee’s March report concluded it was not convinced that the menstrual and gynaecological needs of young women and girls had been sufficiently prioritised in wider healthcare reforms.

It followed the committee’s 2024 “medical misogyny” report, which found women with painful reproductive health conditions such as endometriosis, adenomyosis and heavy menstrual bleeding were frequently finding their symptoms “normalised” and their “pain dismissed” when seeking help.

In both reports, MPs called on the government to recognise the benefits of increased investment in early diagnosis and treatment of women’s reproductive health conditions and provide additional funding needed to transform the support available to millions of women.

In its response, published on 26 May as a command paper, the Department of Health and Social Care outlined action on reducing gynae waiting times, ensuring procedures are conducted with women’s full consent and adequate pain relief, and improving access to contraception for menstrual healthcare in line with the committee’s recommendations.

It said: “The government agrees with the committee’s overarching findings and recommendations for improving women’s health outcomes and experiences.

“We acknowledge the impact that menstrual health conditions can have on women’s lives, relationships, and participation in education and the workforce.

“We recognise that more needs to be done to support women with menstrual health conditions, particularly around listening to women, improving information and education, and enhancing patient experience.”

However, there was no commitment to increase school nurse provision, no measurable actions and targets on countering online misinformation, no new commitments to end inappropriate censorship of women’s online health content, and no further initiatives on tackling racial discrimination or understanding the menstrual wellbeing needs of young disabled and Deaf women.

The response comes after analysis by The Times suggested the government is allocating 60 per cent more funding to its men’s health strategy than to its renewed strategy for women’s health.

Sarah Owen, chair of the Women and Equalities Committee and Labour MP, said: “WEC’s 2024 ‘medical misogyny’ report warned 18 months ago of women in unnecessary pain and undiagnosed for years and called on the Government to recognise the benefits of increased investment in early diagnosis and treatment.

“Our follow up report this March cautioned girls’ and women’s health are not being sufficiently prioritised in system-wide NHS reforms, while initiatives which have proven to be successful in reducing waiting lists and improving women’s healthcare access, such as women’s health hubs, risked being scaled back or discontinued.

“While it’s welcome to see a focus on tackling ‘medical misogyny’ in April’s renewed Women’s Health Strategy and an emphasis on women’s voices being heard, this must be backed by adequate funding, not financial half measures, particularly when compared to men’s health.

“Significant questions remain following today’s response publication over the adequacy of investment being provided, including for workforce training, menstrual health education in schools, research and additional ring-fenced funding for women’s health hubs to deliver services within the emerging neighbourhood health framework.

“There are both opportunities and risks when it comes to increasing use of technology in women’s healthcare.

“As the Committee’s report set out, social media companies should be held to account for inappropriate and disgraceful ‘shadow banning’ censorship of important women’s health content and there should be a rigorous approach to tackling the risks from ineffective, unsafe and exploitative for-profit FemTech apps.

“The Government should take the problem of ‘shadow banning’ more seriously.

“A strategy which does not fully address the concerns set out in WEC’s report, alongside measurable actions and timescales, will only scratch the surface of the issues facing women’s health.

“WEC will keep a close eye on progress and continue to push for long overdue tangible change for women and girls.”

Continue Reading

Cancer

Early PET scan could chemo response in aggressive breast cancer – study

Published

on

An early PET scan after one cycle of chemotherapy may help predict how aggressive breast cancer responds to treatment, a study suggests.

Research led by The Institute of Cancer Research, London and King’s College London suggests that an early scan taken after one cycle of chemotherapy could help predict how well a patient’s cancer will respond to treatment.

The study focused on patients with triple-negative breast cancer (TNBC), an aggressive form of the disease in which cancer cells lack receptors for the hormones oestrogen and progesterone, as well as the HER2 protein.

Patients with TNBC are usually treated with chemotherapy prior to surgery. While many respond well, residual disease at surgery, typically around six months later, is associated with a significantly poorer prognosis. Identifying people sooner who are unlikely to respond remains a major clinical challenge.

The research explored whether using PET imaging shortly after treatment begins, rather than relying only on MRI scans later in the treatment process, could provide earlier insight into how a patient’s cancer is responding. Twenty-two patients were recruited, with fourteen undergoing FDG-PET scans before treatment and after the first cycle of chemotherapy.

The findings, published in Clinical Cancer Research, showed that changes seen on PET scans after just one cycle of chemotherapy were strongly associated with subsequent response, including whether there was no detectable cancer, known as a complete response, by the end of treatment. Importantly, early PET response showed stronger associations with treatment outcomes than standard mid-treatment MRI scans in this study.

Being able to identify patients who are not responding well at an early stage could allow clinicians to adjust treatment sooner or consider alternative approaches. These findings may also support future strategies to better tailor treatment intensity to individual patients.

The study also compared two types of PET tracers, FDG and FLT, to determine which was most suitable. While both met the study’s technical criteria, FDG-PET was selected for further evaluation due to its better image quality, greater consistency and wider use in clinical practice.

The research also explored how imaging changes after just one cycle of chemotherapy relate to the body’s immune response to treatment. Biopsies taken before and after the first cycle of chemotherapy showed that an increase in immune cells within the tumour was strongly associated with both early PET changes and improved treatment outcomes.

The researchers emphasise that these findings now need to be validated in larger studies. Future work will aim to confirm these results in broader patient groups and explore more accessible imaging approaches, such as ultrasound, alongside PET and MRI.

Sheeba Irshad, professor of cancer immunology at King’s College London and lead of the Breast Cancer Now KCL Research Unit, said:

“In patients who had PET scans both before treatment and after the first cycle, we found that this early scan could predict whether they were likely to achieve a complete response by the end of treatment. These findings highlight the potential of early imaging to guide treatment decisions, and now need to be validated in larger, modern clinical trials.”

Andrew Tutt, professor of breast oncology at The Institute of Cancer Research, London, said:

“Research that helps us determine early who is already benefitting from standard neoadjuvant chemotherapy and who might benefit from clinical trials to find better treatments is vital. This study shows that FDG-PET may have great value in this regard. We hope to be able to design studies that further investigate and validate these findings.”

The study was supported by funding from King’s College London and Guy’s and St Thomas’ NHS Foundation Trust, Breast Cancer Now, Cancer Research UK, and Guy’s and St Thomas’ Charity.

Continue Reading

Insight

Common cancer marker may play active role in preventing the disease, study finds

Published

on

Ki-67, a protein used to measure tumour growth, may also help prevent chromosome errors that drive cancer, a study suggests.

The findings could change how scientists view Ki-67, a marker commonly used in breast cancer and other tumours to assess how quickly cancer cells are growing.

Researchers found the protein may help preserve genome stability by maintaining the structural integrity of centromeres, key parts of chromosomes that help ensure DNA is shared correctly during cell division.

The research was led by professor Paola Vagnarelli at Brunel University of London in collaboration with scientists at the University of Edinburgh and the Technical University of Berlin.

Professor Vagnarelli said: “Doctors already measure Ki-67 to see how aggressive a cancer might be. But our results suggest it is actually helping maintain genome stability.

“That means it may be more than a marker. It could potentially also be a therapeutic target.”

The study examined three proteins that attach to chromosomes during cell division and help rebuild the molecular system that tells each new cell what kind of cell it is.

Every human cell carries identical DNA. What makes a liver cell different from a brain cell is which genes are switched on and which are kept inactive.

When a cell divides, that entire system of switches must be rebuilt. The three proteins involved in this process were Ki-67, Repo-Man and PNUTS.

Vagnarelli’s team developed a method that individually removes each protein from a living cell at the precise point of division. Older techniques could not isolate that moment cleanly.

They found that cells rely on all three proteins to reset themselves after division, but each failed in a different way when removed.

Without PNUTS, gene activity spiralled out of control and thousands of genes switched on at once.

Without Repo-Man, cells escaped safety checkpoints that usually stop damaged or abnormal cells from continuing to divide.

“What we didn’t expect was how clean the separation was,” said Vagnarelli.

Each protein fails in its own specific way. There is no redundancy, no safety net. Which means there are three separate points at which this process can go wrong.

“When the system breaks down, cells can emerge with the wrong number of chromosomes. That condition, called aneuploidy, is seen in disorders such as Down syndrome and in many cancers.

“We also found that these chromosome errors can trigger inflammatory signals inside the cell.”

Aneuploidy means a cell has too many or too few chromosomes, which can disrupt normal growth and function.

Inflammatory signals are chemical messages that can make a cell behave as if it is responding to injury or infection.

“These cells behave almost as if they are under attack,” said Vagnarelli.

“The immune response switches on because the genome is unstable.

“That link between chromosome imbalance and inflammation could help explain patterns we see in several diseases.”

The researchers said the findings may help cancer scientists better understand how chromosome instability, loss of gene regulation and cells dividing before they are ready contribute to tumour growth.

They said understanding the normal machinery that prevents these errors may help researchers find ways to push cancer cells into making mistakes they cannot survive.

“We now have a clearer map of the machinery that resets the cell after division,” said Vagnarelli.

“That knowledge gives us a starting point for thinking about new therapeutic approaches.”

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.